Los puntos clave no están disponibles para este artículo en este momento.
The use of low-dose TMP/SMX is associated with reduced risk of severe infections in patients with AAV treated with either RTX or CYC/AZA. Reduced B cell subpopulations at start of treatment might be a useful correlate of reduced immunocompetence.
Odler et al. (Thu,) studied this question.